Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Talecris Biotherapeutics Holdings Corp. | a11-1850_2ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 23, 2011
TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-34473 |
|
20-2533768 | ||
|
|
| ||||
P.O. Box 110526 Research Triangle Park, North Carolina |
|
27709 | ||||
(Address of principal executive offices) |
|
(Zip Code) | ||||
Registrants telephone number, including area code: (919) 316-6300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On February 23, 2011, Talecris Biotherapeutics Holdings Corp. issued a press release announcing its financial results for the three and twelve months ended December 31, 2010. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
The information in this report, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
No. |
|
Description |
|
|
|
99.1 |
|
Press Release dated February 23, 2011 |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
TALECRIS BIOTHERAPEUTICS | |
|
HOLDINGS CORP. | |
|
|
|
|
By: |
/s/ John Hanson |
|
Name: |
John Hanson |
|
Title: |
Executive Vice President and Chief Financial Officer |
|
|
|
|
|
|
Date: February 23, 2011